The p53 tumor suppressor gene is frequently mutated within its evoluti
onarily conserved regions in a number of human cancers. Previous repor
ts demonstrated mutations of this gene in both Burkitt's lymphoma and
B cell chronic lymphocytic leukemia. However, dissimilar results were
obtained in non-Hodgkin's lymphoma (NHL). In one study, no mutation wa
s detected in 43 NHL tissues. A second study reported p53 mutations in
eight (all with advanced stage disease) out of 48 tissues obtained fr
om Japanese NHL patients. Using both immunoblotting and radio-immunopr
ecipitation, we detected mutant p53 proteins in nine out of 10 B cell
lines established from NHL tissues. The mutations were confirmed by re
verse transcription polymerase chain reaction-mediated single-strand c
onformational polymorphism (RT-PCR-SSCP) analysis in eight cell lines.
The high frequency of p53 mutation in NHL B cell lines and the relati
vely low frequency of p53 mutations in fresh lymphoma tissue suggests
that p53 gene alteration may play a role in lymphomagenesis and/or dis
ease progression in a subset of B cell lymphomas and that the p53 muta
tion conveys a proliferative advantage on lymphoma cells that permits
their in vitro growth.